Health

  • April 06, 2026

    1st Circ. Suggests It May Resurrect AdTech Wiretap Case

    A panel of the First Circuit appeared receptive Monday to reinstating federal wiretap claims leveled against a Massachusetts healthcare system over its use of online tracking tools, despite arguments that such a ruling could cripple the industry amid an influx of similar cases nationwide.

  • April 06, 2026

    Full Fed. Circ. Urged To Course Correct On Design Patent Test

    The full Federal Circuit needs to return design patent infringement to a similarities-focused test, rather than one looking at differences between designs, massage device-maker Range of Motion Products LLC said in a bid to revive its suit against Armaid Co.

  • April 06, 2026

    Cleary FCA Task Force Head On Enforcement Trends To Watch

    Former U.S. Attorney for the Eastern District of New York Breon Peace, who now leads a False Claims Act task force at Cleary Gottlieb Steen & Hamilton LLP, is predicting a continued surge in enforcement as the Trump administration wields the law in new ways.

  • April 06, 2026

    NJ Pharmacy Co. Sued Over Nursing Home Data Exposure

    A New Jersey pharmacy for long-term care facilities is facing a proposed nationwide class action alleging it failed to safeguard highly sensitive patient information later accessed by cybercriminals, according to a complaint filed in federal court.

  • April 06, 2026

    Mass. Justices Hint Insurer Owes Defense In Doc's Discipline

    An allegation that a Massachusetts doctor prescribed addictive medications to manipulate a patient into a sexual relationship could be enough to trigger a malpractice insurer's duty to defend him in a disciplinary proceeding launched years later over other alleged misconduct, justices on the state's highest court hinted Monday.

  • April 06, 2026

    Pfizer Failed To Warn Of Depo-Provera Cancer Risk, Suit Says

    A Georgia woman who alleged she developed a brain tumor after taking the contraceptive drug Depo-Provera sued Pfizer in federal court, claiming the company failed to warn American patients about the danger even though it does so on warning labels in the European Union.

  • April 06, 2026

    WilmerHale Adds Regulatory Atty From Mayer Brown In DC

    WilmerHale announced Monday it has hired a veteran U.S. Food and Drug Administration and life sciences regulatory attorney from Mayer Brown LLP.

  • April 06, 2026

    Catching Up With Delaware's Chancery Court

    The Delaware Chancery Court's docket this past week featured a mix of high-profile corporate disputes, insider trading allegations, contract fights and significant rulings shaping fiduciary duty and deal litigation.

  • April 06, 2026

    Cooley, Wilson Sonsini Steer Neurocrine's $2.9B Soleno Buy

    Neurocrine Biosciences has agreed to acquire biotechnology company Soleno Therapeutics for about $2.9 billion in cash, in a deal advised by Cooley LLP and Wilson Sonsini Goodrich & Rosati PC, the companies said on Monday. 

  • April 06, 2026

    4 Firms Guide Healthcare REIT's Early IPO Steps

    National Healthcare Properties filed Monday for an initial public offering in which the healthcare real estate investment trust preliminarily estimated it could raise $100 million, advised by Paul Weiss Rifkind Wharton & Garrison LLP and two other firms.

  • April 06, 2026

    Justices To Mull Courts' Authority To Hear Vets' Benefits Suits

    The U.S. Supreme Court on Monday agreed to review a U.S. Army veteran's suit challenging the limit on disability benefits available to him as someone convicted of a felony and sentenced to a lengthy prison term, after the Eleventh Circuit dismissed his claims.

  • April 03, 2026

    Case-By-Case Guide As Justices Eye Landmark Pharma Law

    Drugmakers and prominent allies are inundating the U.S. Supreme Court with calls to scrutinize Medicare's new power to slash payments by tens of billions of dollars, and the justices look poised to take up or turn down a fistful of legal challenges in one fell swoop.

  • April 03, 2026

    Wash. DOC Inks Deal Over Trans Treatment In Facilities

    The Washington State Department of Corrections will start improving conditions for transgender, intersex and nonbinary people in its facilities and submit to yearly monitoring, according to a settlement agreement between the agency and a nonprofit in the state.

  • April 03, 2026

    Colo. Doctor Says Centura Lacks Proof For Mitigation Defense

    A doctor who claims Centura Health recruited him for an in-house position and took back a job offer after he disclosed that he was suffering symptoms of burnout asked a judge in Colorado federal court to toss one of the healthcare company's affirmative defenses.

  • April 03, 2026

    Anthem, Wells Fargo Say Patients Received All Benefits Owed

    Insurers urged a Colorado federal judge to allow them to escape claims from a mental health and substance use treatment facilities operator's lawsuit, alleging the facility lacks standing to bring claims under federal benefits and mental health parity laws.

  • April 03, 2026

    States Warn Of Executive Overreach In $100K H-1B Fee Fight

    A group of 20 states challenging the Trump administration's $100,000 fee on H-1B visa petitions slammed its position that the policy isn't reviewable, telling a Massachusetts federal court the government would essentially have a blank check to usurp congressional authority under its rationale.

  • April 03, 2026

    Schneider Wallace Loses Bid For Bigger Piece Of $75M Fee

    A California federal magistrate judge on Friday rejected Schneider Wallace Cottrell Kim LLP's bid to increase its cut of a $75.4 million fee award for representing plaintiffs in a $228.5 million Sutter Health antitrust deal, saying lead counsel Constantine Cannon LLP's allocation of $1.4 million to Schneider Wallace was fair.

  • April 03, 2026

    Legislative Update: Cannabis And Psychedelics Bill Roundup

    State lawmakers in Delaware and West Virginia advanced legislation to more tightly regulate kratom products, Missouri and Kentucky legislators considered bills to fund research into the therapeutic uses of the psychedelic ibogaine, and Idaho's Legislature came together to urge voters to reject a medical marijuana legalization proposal that could be on the ballot this November. Here are the major moves in cannabis and psychedelics legislation from the past week.

  • April 03, 2026

    Bradley Arant Launches Medical Office Real Estate Team

    Bradley Arant Boult Cummings LLP has launched a team focused on medical office buildings real estate led by partners in Nashville, Tennessee, and Dallas.

  • April 03, 2026

    Northwestern Can't Escape ERISA Fight Over Health Offerings

    An Illinois federal court refused to toss a proposed class action against Northwestern University alleging excessive employee healthcare costs violated federal benefits law, concluding ex-workers had sufficiently backed up their allegations that an expensive plan option breached fiduciary duties.

  • April 03, 2026

    Law360 Announces The Members Of Its 2026 Editorial Boards

    Law360 is pleased to announce the formation of its 2026 Editorial Advisory Boards.

  • April 03, 2026

    Ga. Urology Network To Pay $14M To Resolve FCA Case

    An Atlanta urology network and its founder will pay $14 million to settle allegations that they billed Medicare and Medicaid for medically unnecessary procedures, ranging from ultrasounds to endoscopic exams, according to an announcement by federal and Georgia state prosecutors.

  • April 03, 2026

    Aetna Escapes COVID Testing Payment Suit In Calif.

    A Nebraska testing laboratory failed to prove that Aetna underpaid more than $53 million for COVID-19 testing services, a California federal judge has ruled, dismissing the lab's federal racketeering and state law claims against the insurer but leaving the door open to an amended suit. 

  • April 03, 2026

    Greenberg Traurig Adds Former Healthcare GC In Dallas

    Greenberg Traurig LLP has boosted its healthcare and U.S. Food and Drug Administration practice with a shareholder in Dallas who brings substantial in-house experience, most recently serving as general counsel to ophthalmology administrative services provider Sight Growth Partners.

  • April 03, 2026

    NYC Fights Sanctions Over Discovery In IVF Sex Bias Dispute

    New York City urged a federal judge to reject a gay couple's sanctions bid in their suit claiming a municipal health plan blocked them from receiving in vitro fertilization coverage out of discrimination, calling their concerns with the city's sluggish discovery production in the case premature.

Expert Analysis

  • Series

    Law School's Missed Lessons: Intentional Career-Building

    Author Photo

    A successful legal career is built through intention: understanding expectations, assessing strengths honestly and proactively seeking opportunities to grow and cultivating relationships that support your development, say Erika Drous and Hillary Mann at Morrison Foerster.

  • 4 Trends Shaping Drug And Medical Device Law For 2026

    Author Photo

    2025 saw some significant legal developments with potential impact for drug and device manufacturers, ranging from growing skepticism in science and regulatory entities to new regulation of artificial intelligence, say attorneys at Faegre Drinker.

  • Key Trends In Healthcare Antitrust In 2025

    Author Photo

    The healthcare industry braced for significant antitrust enforcement shifts last year driven by a change in administration, and understanding the implications of these trends is critical for healthcare organizations' risk management and strategic decision-making in the year ahead, say attorneys at Michael Best.

  • The 5 Most Important Bid Protest Decisions Of 2025

    Author Photo

    In a shifting bid protest landscape, five decisions in 2025 from the Federal Circuit, the U.S. Court of Federal Claims and the U.S. Government Accountability Office that addressed bedrock questions about jurisdictional reach and the breadth of agency discretion are likely to have a lasting impact, say attorneys at Bradley Arant.

  • Food Industry Braces For MAHA And Other Challenges In 2026

    Author Photo

    After the Make America Healthy Again movement kept the U.S. Food and Drug Administration under pressure in 2025, actions in the food safety space are likely to continue this year, including updated Supplemental Nutrition Assistance Program dietary guidelines and processed food definitions, say attorneys at Wiley.

  • Preparing For Congressional Investigations In A Midterm Year

    Author Photo

    2026 will be a consequential year for congressional oversight as the upcoming midterm elections may yield bolder investigations and more aggressive state attorneys general coalitions, so companies should consider adopting risk management measures to get ahead of potential changes, say attorneys at Morgan Lewis.

  • A Meaningful Shift In FDA's Biosimilarity Analysis

    Author Photo

    The U.S. Food and Drug Administration's potential pivot away from routinely requiring comparative efficacy studies for interchangeable biosimilar applications would not lower regulatory standards, but instead allow applicants to allocate resources toward establishing more probative evidence, says Theodore Thompson at Stinson.

  • Employment Immigration Trends And Challenges For 2026

    Author Photo

    U.S. companies competing for global talent should brace for a turbulent 2026, with greater compliance burdens, higher costs and the probability of workforce disruptions at every stage of the immigration process, from visa petitions to work authorization renewals, say attorneys at Duane Morris.

  • Top 5 Antitrust Issues For In-House Counsel To Watch In 2026

    Author Photo

    With Trump administration enforcement policy having largely taken shape last year, antitrust issues that in-house counsel should have on the radar range from scrutiny of technology-assisted pricing to the return of merger remedies, say attorneys at Squire Patton.

  • 4 Developments That Defined The 2025 Ethics Landscape

    Author Photo

    The legal profession spent 2025 at the edge of its ethical comfort zone as courts, firms and regulators confronted how fast-moving technologies and new business models collide with long-standing professional duties, signaling that the profession is entering a period of sustained disruption that will continue into 2026, says Hilary Gerzhoy at HWG Law.

  • Navigating AI In The Legal Industry

    Author Photo

    As artificial intelligence becomes an increasingly integral part of legal practice, Law360 guest commentary this year examined evolving ethical obligations, how the plaintiffs bar is using AI to level the playing field against corporate defense teams, and the attendant risks of adoption.

  • How Fractional GCs Can Manage Risks Of Engagement

    Author Photo

    As more organizations eliminate their in-house legal departments in favor of outsourcing legal work, fractional general counsel roles offer practitioners an engaging and flexible way to practice at a high level, but they can also present legal, ethical and operational risks that must be proactively managed, say attorneys at Boies Schiller.

  • Health, Legal Employers Face Unique Online Speech Hurdles

    Author Photo

    Employers in the legal and healthcare industries must consider distinctive ethical obligations and professional requirements when disciplining employees for social media posts, while anticipating an area of the law in flux as courts seek to balance speech rights and the workplace function, say attorneys at FordHarrison.

  • Reviewing 2025's Most Pertinent Wiretap Developments

    Author Photo

    2025 was a remarkable year in the world of web tracking wiretapping litigation, not only for the increased caseload but also because of numerous developing theories of liability, with disputes expected to continue unabated in 2026, say attorneys at Squire Patton.

  • 2025 Legal Milestones That Will Shape Psychedelics Sector

    Author Photo

    As 2025 draws to a close, psychedelic drug development stands at an inflection point, experiencing unprecedented momentum through recent sweeping regulatory changes and landmark clinical milestones, amid rapidly evolving regulatory expectations, say Odette Hauke at Odette Alina LLC and Kimberly Chew at Husch Blackwell.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Health archive.